Original article
Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease?
El uso de secukinumab tras la terapia anti-TNF es mayor de lo esperado por el riesgo de desarrollar enfermedad inflamatoria intestinal?
Fatih Albayraka,
, Mustafa Gürb, Ahmet Karataşb, Süleyman Serdar Kocab, Bünyamin Kısacıkc
Corresponding author
a Department of Internal Medicine, Division of Rheumatology, Dr. Ersin Arslan Training and Research Hospital, Şehitkamil, Gaziantep, Turkey
b Department of Internal Medicine, Division of Rheumatology, Fırat University Faculty of Medicine, Elazığ, Turkey
c Department of Rheumatology, Gaziantep Sanko Hospital, Şehitkamil, Gaziantep, Turkey
Read
2011
Timeswas read the article
793
Total PDF
1218
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 11 | 349 | 33 | 382 |
| 2025 10 | 43 | 80 | 123 |
| 2025 9 | 0 | 78 | 78 |
| 2025 8 | 0 | 57 | 57 |
| 2025 7 | 0 | 61 | 61 |
| 2025 6 | 5 | 32 | 37 |
| 2025 5 | 139 | 64 | 203 |
| 2025 4 | 99 | 45 | 144 |
| 2025 3 | 63 | 40 | 103 |
| 2025 2 | 60 | 47 | 107 |
| 2025 1 | 60 | 61 | 121 |
| 2024 12 | 170 | 34 | 204 |
| 2024 11 | 62 | 86 | 148 |
| 2024 10 | 87 | 40 | 127 |
| 2024 9 | 72 | 33 | 105 |
| 2024 8 | 8 | 0 | 8 |
| 2024 6 | 1 | 2 | 3 |
Show all
